<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357719</url>
  </required_header>
  <id_info>
    <org_study_id>1308191</org_study_id>
    <secondary_id>2014-A01733-44</secondary_id>
    <nct_id>NCT02357719</nct_id>
  </id_info>
  <brief_title>Effectiveness of VistaO2 FLUX Device in Screening of Sleep Apnea/Hypopnea Syndrome</brief_title>
  <acronym>VISTAO2_FLUX</acronym>
  <official_title>Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novacor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The high prevalence (9% in men and 4% in women) of sleep apnea / hypopnea syndrome (SAHS) in
      adults is now well documented as well as its cardiovascular repercussions. Previous studies
      showed a conclusive link between SAHS and severe cardiovascular diseases such as
      hypertension, myocardial infarction, heart failure and stroke.Then, SAHS is a public health
      issue in adults.

      In this context, early detection of such a disease is crucial if the management is tailored
      to the patient, the practitioner's choice of therapy moving towards continuous positive
      airway pressure (CPAP) or mandibular advancement device. The detection is based on full
      nocturnal polysomnography or polygraphic recordings. Polysomnography remains the gold
      standard but it is a time consuming and costly examination. Polygraphic recording is a test
      that allows simplified the diagnosis of severe patients, but may not be sufficient for mild
      form of SAHS. Thus, the SAHS is a pathology under-diagnosed and under-treated. The validation
      of a technique for identifying patients most at risk to either limit the number of
      polysomnographic examination is requested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this perspective, the development of a product screening sleep related breathing disorders
      for physicians, cardiologists, internists (not specialized sleep experts) would fill this
      need. It allows for a reliable first screening for their patients in parallel with a routine
      cardiological examination. Imposing a minimal human and material, the ECG Holter recorder
      &quot;VistaO2 FLUX&quot; (NOVACOR, Rueil-Malmaison, France) is a device designed to meet these
      requirements. This device fits into the daily management of patients with cardiac arrhythmias
      or sinus/atrioventricular conduction disorders, and of patients suffering myocardial
      infarction (arrhythmic risk stratification, detection of silent myocardial ischemia).

      Analysis of heart rate variability (HRV) has already shown interest in screening SAHS. We
      therefore wish to evaluate the performance of the analysis of data from the screening tool
      VistaO2 FLUX face what the gold standard synchronized polysomnography.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep apnea hypopnea syndrome</measure>
    <time_frame>Day 1</time_frame>
    <description>Apnea hypopnea index higher than 15, evaluated by polysomnography.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <arm_group>
    <arm_group_label>VistaO2 FLUX device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VistaO2 FLUX device</intervention_name>
    <description>Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.</description>
    <arm_group_label>VistaO2 FLUX device</arm_group_label>
    <other_name>VistaO2 FLUX : ECG Holter recorder (Novacor, Rueil-Malmaison, France).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sleep apnea hypopnea syndrome suspicion

          -  written consent

        Exclusion Criteria:

          -  pacemaker

          -  diabetes

          -  atrial fibrillation

          -  electrode allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric ROCHE, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric ROCHE, MD PhD</last_name>
    <phone>+33(0)477828300</phone>
    <email>frederic.roche@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sébastien CELLE, PhD</last_name>
    <phone>+33(0)477828300</phone>
    <email>scelle@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Pitié Salpetrière - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carole PHILIPPE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric ROCHE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude BARTHELEMY, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Apnea Syndromes</keyword>
  <keyword>Polysomnography</keyword>
  <keyword>Holter ECG</keyword>
  <keyword>Thoracic impedance</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Nasal flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

